Accurate tracking and traceability are critical in managing the gene and cell therapy supply chain. When the correct patient needs to be given the correct dose at the correct time, this makes the entire process contingent on the accuracy of patient information and tracking of the material. Life Sciences companies looking to consolidate their gene and cell therapy processes into their central SAP S/4HANA (or even ECC) ERP platform require a robust solution to service these needs and leverage existing capabilities. Clarkston’s SAP-based CTOP Platform (Gene and Cell Therapy Orchestration Platform) combines deep Life Sciences Industry and SAP expertise to provide that very solution.
In this 12-minute informational video and platform demo, we walk you through the unique Cell Therapy Orchestration Platform product demo which demonstrates our end-to-end software for cell and gene orchestration, state-of-the-art patient scheduling capabilities, and robust chain of identity reporting to streamline manufacturer and clinician processes.
Clarkston’s CTOP Solution provides a platform to manage integrated, collaborative, and up-to-date communication and visibility across all stakeholders including clinical sites, couriers, and therapy administration clinics. Dashboard-style interactive reporting enables drill down capabilities to the information at the stakeholder level based on business functions. Clarkston’s CTOP Solution can be leveraged by a Cell Therapy Sponsor, Clinic, or CMO to manage their operations and provide a holistic view across their entire cell-therapy therapy product lines. Some of the key macro business process areas which can be managed by CTOP are Patient Enrollment, Patient Appointment Scheduling, In-bound Transit, Cell-Collection Processing, Manufacturing Updates, Outbound Transit, and Treatment Infusion Scheduling.
Download this 12-minute video demo on-demand to learn more about how Clarkston’s Cell Therapy Orchestration platform run on SAP enables seamless production and administration of innovative cell and gene therapies.